Skip to main content
Evidence Snapshot

Complement factor B

CHEMBL5731 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5731
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Complement factor B as ChEMBL target CHEMBL5731, mapped to UniProt P00751. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Complement factor B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5731
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00751
Complement factor B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Complement factor B matters

As of 2026-09-13

Complement factor B is reviewed as Complement factor B (UniProt P00751); Complement factor B shows approved-linked disease relevance led by acquired paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 197 compounds, and 33 assays, with lead potency reaching pChEMBL 11.0.

Disease context
acquired paroxysmal nocturnal hemoglobinuria

Complement factor B shows approved-linked disease relevance led by acquired paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include IPTACOPAN, IPTACOPAN HYDROCHLORIDE.

Start review with acquired paroxysmal nocturnal hemoglobinuria because it currently carries approved-linked support. Linked drugs include IPTACOPAN, IPTACOPAN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 197 compounds, and 33 assays for this target. The dominant activity type is IC50. CHEMBL4594448 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4594448 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Complement factor B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00751, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acquired paroxysmal nocturnal hemoglobinuria is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

197
Total Compounds
33
Total Assays
2
Approved Drugs
IC50: 338.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4594448
 11.0 IC50 Approved
No preferred name
CHEMBL5778053
 11.0 IC50 —
No preferred name
CHEMBL5804420
 11.0 IC50 —
No preferred name
CHEMBL5932429
 11.0 IC50 —
No preferred name
CHEMBL5981804
 11.0 IC50 —

Approved Drugs

Structure Compound First Approval
IPTACOPAN
CHEMBL4594448
 2023
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5731